GD
PDSB icon

Grandfield & Dodd’s PDS Biotechnology PDSB Stock Holding History

Grandfield & Dodd’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.05K Hold
10,000
– – ﹤0.01% 209
2025
Q4 		$7.7K Hold
10,000
– – ﹤0.01% 207
2025
Q3 		$10.1K Hold
10,000
– – ﹤0.01% 211
2025
Q2 		$13.3K Buy
+10,000
New +$13.6K ﹤0.01% 212

Other funds holding PDSB

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Grandfield & Dodd's PDSB Position: Q1 2026 in Review

Grandfield & Dodd held its PDS Biotechnology (PDSB) position steady in Q1 2026 at 10,000 shares worth $6.05K. The position accounts for ﹤0.01% of the portfolio, ranked #209.

Grandfield & Dodd first reported a position in PDSB in Q2 2025 and has held it in 4 quarters since. The position peaked at $13.3K in Q2 2025. 41 funds tracked by Wall St. Rank hold PDSB as of Q1 2026.

  • Grandfield & Dodd held 10,000 shares of PDS Biotechnology worth $6.05K as of Q1 2026.
  • Grandfield & Dodd left its PDS Biotechnology share count unchanged in Q1 2026.
  • PDS Biotechnology made up ﹤0.01% of Grandfield & Dodd's portfolio in Q1 2026, its #209 holding.
  • Grandfield & Dodd first reported a position in PDS Biotechnology in Q2 2025 and has held it in 4 quarters since.
  • Grandfield & Dodd's PDS Biotechnology position peaked at $13.3K in Q2 2025.
  • 41 funds tracked by Wall St. Rank held PDS Biotechnology as of Q1 2026.

Based on Grandfield & Dodd's 13F filing for Q1 2026, filed 7 May 2026.